brentuximab vedotin sold brand name adcetris antibodydrug conjugate medication used treat relapsed refractory hodgkin lymphoma hl systemic anaplastic large cell lymphoma alcl type cell nonhodgkin lymphoma selectively targets tumor cells expressing antigen defining marker hodgkin lymphoma drug jointly marketed millennium pharmaceuticals outside us seagen united states brentuximab vedotin indicated treatment hodgkin lymphoma systemic anaplastic large cell lymphoma primary cutaneous anaplastic large cell lymphoma mycosis european union brentuximab vedotin indicated treatment hodgkin lymphoma systemic anaplastic large cell lymphoma cutaneous cell brentuximab consists chimeric monoclonal antibody brentuximab targets cellmembrane protein linked maleimide attachment groups cathepsincleavable linkers valinecitrulline paraaminobenzylcarbamate spacers three five units antimitotic agent monomethyl auristatin e mmae reflected vedotin drugs peptidebased linker bonds antibody cytotoxic compound stable manner drug easily released antibody physiologic conditions help prevent toxicity healthy cells ensure dosage efficiency peptide antibodydrug bond facilitates rapid efficient drug cleavage inside target tumor cell antibody part drug binds often occurs diseased cells rarely normal tissues antibody portion drug attaches surface malignant cells delivering mmae responsible antitumour bound brentuximab vedotin internalised endocytosis thus selectively taken targeted cells vesicle containing drug fused lysosomes lysosomal cysteine proteases particularly cathepsin b start break valinecitrulline linker mmae longer bound antibody released directly tumor environment brentuximab vedotin studied monotherapy patients two phase ii trials across trials common adverse reactions regardless causality chemotherapyinduced peripheral neuropathy progressive enduring often irreversible tingling numbness intense pain hypersensitivity cold beginning hands feet sometimes involving arms legs neutropenia immune system impairment fatigue nausea anemia upper respiratory tract infection diarrhea fever rash thrombocytopenia cough january fda announced brentuximab vedotin linked two cases progressive multifocal leukoencephalopathy requiring addition black box warning drug label regarding potential august us food drug administration fda granted accelerated approval biologics license application bla submitted seattle genetics use brentuximab treatment relapsed hl october european medicines agency ema gave conditional marketing authorization relapsed refractory hl november fda approved brentuximab vedotin treatment patients cutaneous tcell lymphoma ctcl received prior systemic approval patients primary cutaneous anaplastic large cell lymphoma pcalcl mycosis fungoides march fda approved brentuximab vedotin treat adults previously untreated stage iii iv classical hodgkin lymphoma chl combination november fda expanded approved use brentuximab vedotin combination chemotherapy adults certain types peripheral tcell lymphoma first fda approval treatment newly diagnosed november fda approved brentuximab vedotin combination doxorubicin vincristine etoposide prednisone cyclophosphamide people aged two years age older previously untreated high risk classical hodgkin first pediatric approval brentuximab australian pharmaceutical benefits advisory committee pbac considered march application manufacturer inclusion brentuximab vedotin pharmaceutical benefits scheme section efficient funding chemotherapy arrangement application accepted committee noted basis inadequate costbenefit medicine would made available generally firstline treatment relapsed refractory systemic anaplastic large cell lymphoma brentuximab vedotin marketed clinical patients refractory hodgkin lymphoma achieved complete remission another partial tumor reductions achieved patients alcl patients tumors shrink least patients tumor reports showed interim phase ii openlabel singlearm study designed evaluate antitumor activity brentuximab vedotin relapsed refractory nhl including bcell neoplasms results demonstrated singleagent brentuximab vedotin induced objective response rate manageable safety profile among advanced diffuse large bcell lymphoma phase iii trial funded millennium pharmaceuticals compared abvd combination chemotherapy drugs doxorubicin bleomycin vinblastine dacarbazine versus aavd combination brentuximab vedotin plus avd doxorubicin vinblastine dacarbazine treatment classical hodgkin lymphoma found substituting brentuximab vedotin bleomycin improved efficacy lowered previously completed phase study demonstrated greater number patients experienced pulmonary toxicity brentuximab vedotinabvd abvd alone pulmonary fibrosis classical adverse effect bleomycin however incidence pulmonary fibrosis brentuximab vedotinabvd arm higher expected historical rate abvd overall patients treated brentuximab vedotin avd achieved complete brentuximab vedotin also investigated substitute vincristine another mitotic inhibitor prevents tubulin polymerization patients treated chop combination cyclophosphamide hydroxydaunorubicin vincristine prednisone prednisolone nonhodgkin lymphoma phase iii clinical trial currentlywhen comparing two combination therapies chop chpbrentuximab vedotin estimated completion december phase trial compared brentuximab vedotin bleomycin combination adriamycin vinblastine dacarbazine avd chemotherapy firstline treatment advanced classical hodgkin outcome trial resulted positive recommendation committee medicinal products human use chmp part combination treatment adults previously untreated stage hodgkin httpsenwikipediaorgwikibrentuximabvedotin